PSMA PET (prostate cancer)

PSMA-PET with 18F-PSMA approved in Switzerland since October 2019. Compared to choline PET, PSMA PET has a significantly higher sensitivity for lymph node and distant metastases and, in contrast to choline PET, can also be used well for initial staging in prostate cancer.

Coronary MIP uptake in this 67-year-old patient provides a first overall view. After a radical prostate resection in 2013, the PSA increased again to currently 0.22 ng/ml. Axial fused images demonstrate focal PSMA enhancement in a pararectal lymph node as small as 3 mm in diameter (yellow arrow). This is therefore, despite the small size suspicious for a lymph node metastasis.

Coronary MIP uptake in this 67-year-old patient provides a first overall view. After a radical prostate resection in 2013, the PSA increased again to currently 0.22 ng/ml. Axial fused images demonstrate focal PSMA enhancement in a pararectal lymph node as small as 3 mm in diameter (yellow arrow). This is therefore, despite the small size suspicious for a lymph node metastasis.

Indications

The following indication is reimbursed by the health insurance:

  • Biochemically proven recurrence (PSA increase) of a prostate carcinoma.
  • The primary staging is also reimbursed by the health insurance for high-risk prostate carcinoma and intermediate-risk prostate carcinoma.
Details see PDF, page 105ff

Responsible doctors

Martin Hüllner, Prof. Dr. med.

Senior Attending Physician, Vice Director of Department, Department of Nuclear Medicine

Tel. +41 44 255 25 80
Specialties: Research group: Hybrid and molecular tumor imaging, PET/CT and PET/MR, SPECT/CT

Lars Husmann, Prof. Dr. med.

Attending Physician, Department of Nuclear Medicine

Tel. +41 43 253 87 99

Cäcilia Mader, Dr. med.

Attending Physician with extended responsibilites, Department of Nuclear Medicine

Tel. +41 43 253 88 02

Alexander Maurer, Dr. med.

Attending Physician with extended responsibilites, Department of Nuclear Medicine

Tel. +41 43 253 88 09
Specialties: Multimodal oncological hybrid imaging (PET/CT and PET/MRI), Imaging of prostate cancer (PSMA PET), SPECT/CT

Michael Messerli, PD Dr. med.

Attending Physician with extended responsibilites, Department of Nuclear Medicine

Tel. +41 43 253 88 03
Specialties: Multimodal oncological imaging, Thoracic imaging, Research group: Hybrid and molecular tumor imaging

For patients

As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.

Tel. +41 44 255 35 55
Contact formular

For referring physicians

Simply assign your patient via registration form.

Tel. +41 44 255 35 55

Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02

Responsible Department